IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#203
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$137.7B
Daniel P. O'Day
Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.
Headcount
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = GILD ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GILD GILEAD SCIENCES, INC. | 67 | 72 | 80 | 64 | 24.8x | 23.8x | 35.3% | 13.0% | 78.7% | 30.8% | 25.8% | 11.7% | 2.8% | 116.0x | $137.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
GILEAD SCIENCES, INC. (GILD) receives a "Buy" rating with a composite score of 66.7/100. It ranks #203 out of 7,333 stocks in our coverage universe and carries a 4-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
17.0K
HQ Base
Foster City, California
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Top-rated overall — multiple factors aligned for strong entry
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for GILD.
View All RatingsROIC 15.3% vs WACC 8.7% (spread +6.6%)
GM 79% vs sector 44%, OM 31% vs sector 3%
Capital turnover 0.44x
Rev growth 12%, 10yr history
Interest coverage 13.0x, Net debt/EBITDA 5.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate GILEAD SCIENCES, INC. (GILD) as a Buy with a composite score of 66.7/100 at a current price of $147.62. The stock scores above average across the majority of our quantitative factors and ranks #203, reflecting a favorable risk-reward profile.
GILEAD SCIENCES, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 66.7/100 places it at rank #203 in our full universe.
The near-term outlook is constructive, with revenue growing at 12% and momentum in the 64th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Narrow
Medium
Exemplary
Undervalued
Gross margins of 79% signal strong pricing power.
Returns on equity of 35.3% exceed cost of capital.
Value factor score of 80 suggests attractive pricing.
Leverage of 116% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
GILEAD SCIENCES, INC. represents a buy based on multi-factor quantitative performance.
GILEAD SCIENCES, INC. receives a Buy rating with a composite score of 66.7/100 and 4 out of 5 stars, ranking #203 of 7,333 stocks in our universe. GILD displays a favorable combination of factors that positions it above the majority of the market. While not without risk, the quantitative profile supports a constructive outlook.
GILD earns a quality score of 72/100, indicating above-average business quality. The company reports a return on equity of 35.3% (sector avg: -1.9%), gross margins of 78.7% (sector avg: 44.1%), net margins of 25.8% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
GILD carries a solid value score of 80/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 24.78x, an EV/EBITDA of 23.84x, a P/B ratio of 8.75x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 42/100, GILD exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 11.7% vs. a sector average of 6.7% and a return on assets of 13.0% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
GILD demonstrates moderate momentum with a score of 64/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 11.7% year-over-year, while a beta of 0.38 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
GILEAD SCIENCES, INC. earns an excellent stability score of 89/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.38 and a debt-to-equity ratio of 116.00x (sector avg: 0.2x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
The short interest score of 53/100 for GILD suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 116.00x). With a $137.7B market cap (large-cap), GILEAD SCIENCES, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
GILD pays a solid dividend yield of 2.8%, contributing an income component to total returns. This moderate yield suggests a balance between returning capital to shareholders and retaining earnings for reinvestment — a common profile among quality compounders.
GILEAD SCIENCES, INC. is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #203 of 7,333 overall (97th percentile). Key comparisons include ROE of 35.3% exceeding the -1.9% sector median and operating margins of 30.8% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
Quant Factor Profile
Key factor gap
Stability (89) vs Investment (42) — closing this gap could shift the rating.
EV/EBITDA 108% ABOVE SECTOR MEDIAN
ROE 1959% BELOW SECTOR MEDIAN
Gross Margin 79% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
About GILEAD SCIENCES Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread
Software stocks declined sharply with the iShares Tech-Expanded Software Sector ETF (IGV) falling over 3%, while major U.S. indexes posted modest gains. The January jobs report showed strong headline numbers but disappointing revisions, with 2025 job growth at its weakest since 2003. Bitcoin dropped over 3% to $66,000, and notable losers included Unity Software, Mattel, and Zillow, while semiconductors and energy stocks outperformed.
Gilead Sciences (NasdaqGS:GILD) has agreed to acquire cancer therapy developer Arcellx in a deal valued at US$7.8b. The transaction will give Gilead full control of anito cel, a late stage CAR T cell therapy for multiple myeloma. An FDA approval decision for anito cel is expected later this year. This is Gilead's largest acquisition since 2020 and expands its presence in oncology and cell therapy. Gilead Sciences is best known for its antiviral and HIV treatments. In recent years it has...
Gilead Sciences announced a definitive agreement to acquire biotechnology company Arcellx for approximately $7.8 billion ($115 per share in cash), representing a 68% premium to Arcellx's 30-day volume-weighted average price. The deal includes a contingent value right of $5 per share if anito-cel, Arcellx's lead CAR-T therapy, reaches $6 billion in cumulative global net sales by end of 2029. The acquisition is expected to close in Q2 2026 and expands Gilead's existing collaboration with Arcellx on the investigational BCMA-directed CAR-T cell therapy for multiple myeloma.
Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell therapy activities. Management emphasized that the company ended 2025 with roughly €3 billion in cash,